View Financial HealthAdhera Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Adhera Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 19Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive OfficerOn January 12, 2024, Adhera Therapeutics, Inc. received notice from Zahed Subhan that he was resigning as the company’s Chief Executive Officer and as a member of the Board of Directors. Mr. Subhan’s decision to resign as Chief Executive Officer and member of the company’s Board of Directors was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.공시 • Jan 18Adhera Therapeutics, Inc. Announces Board ResignationsOn January 9, 2024, Adhera Therapeutics, Inc. received notice from Trond K. Waerness that he was resigning from Board of Directors effective January 12, 2024. Mr. Waerness’ decision to resign as director was not the result of any disagreement with the company on any matter relating to the Company’s operations, policies, or practices. Further, on January 12, 2024, the company received notice from Zahed Subhan that he was resigning as the company’s Chief Executive Officer and as a member of the Company’s Board of Directors. Mr. Subhan’s decision to resign as Chief Executive Officer and member of the Company’s Board of Directors was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.공시 • Nov 17Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 11/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 17Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 16Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 05/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jan 26Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 DiabetesAdhera Therapeutics, Inc. announced that the company is to commence a dose finding study of MLR-1023 (tolimidone) in Type 1 Diabetes in collaboration with the Alberta Diabetes Institute (ADI) at the University of Alberta (U of A), located in Edmonton, Alberta, Canada. The company and U of A are finalizing the details of the trial, which are expected to be released shortly. The results of the study will also be utilized to optimize the dose range used in Adhera’s forthcoming Phase 2 multi-center clinical trial of MLR-1023 in Type 1 Diabetes. It is anticipated that the ADI will also participate in the multi-center study. MLR-1023, a lyn kinase activator with potent beta cell proliferation activity, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies. Adhera will focus its initial clinical trials on patients with Type 1 Diabetes where the Company can benefit from several factors, including the existing safety profile, which is expected to undergird the drug candidate moving directly into Phase 2 clinical trials and a shorter and less expensive clinical pathway compared to Type 2 Diabetes. Independent research has demonstrated robust therapeutic effects of MLR-1023 in Type 1 Diabetes preclinical models. There is a large addressable market due to the lack of alternative treatment options in Type 1 Diabetes aside from insulin injections or an insulin pump. In Type 1 Diabetes patients, the pancreas produces little to no insulin. At a cellular level, the immune system attacks pancreatic beta cells that produce insulin, leaving the patient with deficient levels of insulin to control blood glucose and a resulting dependency on exogenous insulin. Approximately 20%-30% of Type 1 Diabetes patients have demonstratable amounts of beta cell mass as determined by detectable amount of the insulin synthesis byproduct, C-peptide. Research indicates the potential for MLR-1023 to induce proliferation of a patient’s remaining beta cells. Adhera, alongside independent researchers, hypothesize that if the beta cell mass can be expanded in the C-peptide positive patient population, it may be possible to either reduce or eliminate the exogenous insulin requirement. In addition to the U of A trial, the company is pleased to inform shareholders that progress is being made towards filing an application to uplist to the NASDAQ, a milestone that should yield additional liquidity and allow the Company to secure financing for clinical trials for both MLR-1019 for Parkinson’s Disease and MLR-1023 for Type 1 Diabetes.공시 • Sep 10+ 1 more updateAdhera Therapeutics, Inc. Announces CEO Changes, Effective September 30, 2022Adhera Therapeutics, Inc. appointed Zahed Subhan as the Company’s Chief Executive Officer, effective September 30, 2022. Mr. Kucharchuk will continue to serve as the Company’s Chief Executive Officer until September 30, 2022. Mr. Subhan, 64, has been serving as the Company’s director since November 5, 2021. He has served as the Chief Executive Officer and director of Aestas Pharma Inc. since 2015. Mr. Subhan has also been a director of Eppin Pharma Inc. (“Eppin”) since 2013, and the Chief Executive Officer of Eppin from 2013 to 2018. Mr. Kucharchuk, 41, has served as the Chairman of Board and Chief Executive Officer since July 7, 2020. He has also served on the Board of Directors of Theralink Technologies, Inc. since 2020 after previously serving in such role from September 2015 to March 2017. Previously, he served as President and Chief Financial Officer of Theralink from February 2016 until June 2020, as Chief Executive Officer of Theralink from November 2019 until June 2020, and as Chief Financial Officer of Theralink from 2009 to September 2015. Mr. Kucharchuk has also served as Acting Chief Financial Officer of Theralink from June 2020 to September 2020.공시 • Jul 20Adhera Therapeutics, Inc. (OTCPK:ATRX) enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group.Adhera Therapeutics, Inc. (OTCPK:ATRX) enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group on July 19, 2022. While best efforts are anticipated to advance the Heads of Terms agreement to an executed definitive agreement pursuant to which Adhera will acquire PGT, no assurances of such a development are expressed, implied, or guaranteed.공시 • Jun 29Adhera Therapeutics, Inc., Annual General Meeting, Aug 18, 2022Adhera Therapeutics, Inc., Annual General Meeting, Aug 18, 2022, at 10:00 US Eastern Standard Time. Agenda: To elect four directors for a one-year term expiring at the next annual meeting of stockholders; to ratify the selection of Salberg & Company, P.A. as the Company’s independent registered public accounting firm for the year ending December 31, 2022; to approve amendment(s) to the Company's Certificate of Incorporation to effect one or more reverse stock splits of the Company's issued and outstanding shares of common stock, par value USD 0.006 per share, at a ratio to be determined in the discretion of the Company's Board of Directors within a range of one-for-two through one-for-200, provided that in no event shall such amendments collectively exceed a reverse stock split ratio of one-for-200; and to consider other matters.공시 • May 20+ 1 more updateAdhera Therapeutics, Inc. Planning to Initiate A Phase 2 Clinical Trial of Mlr-1023 as new Treatment for Type 1 DiabetesAdhera Therapeutics, Inc. announced that it is planning to initiate a Phase 2 clinical trial of MLR-1023 as anew treatment for Type 1 Diabetes where its role in pancreatic beta cell protection and proliferation represents a potential major breakthrough in diabetes care. MLR-1023 is a next generation, non-PPAR insulin sensitizer via lyn kinase activation that has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and 2b diabetes studies. The active pharmaceutical ingredient (API) for this trial has already been manufactured. The Company is also actively working to initiate a Phase 2a study to evaluate MLR-1019 for Parkinson’s Disease. To the best of the Company’s knowledge, MLR-1019 is the only drug in development that has the potential to address both movement and non-movement aspects of the disease. The trial is designed to enroll Parkinson’s Disease patients with L-DOPA induced dyskinesia, a frequent and potential disabling motor side effect of levodopa therapy. The API for this trial has now entered the manufacturing process.공시 • Apr 03Adhera Therapeutics, Inc. announced delayed annual 10-K filingOn 04/01/2022, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 24Adhera Therapeutics, Inc. Contemplates BankruptcyAdhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of November 22, 2021. According to SEC filing, Company is in financial distress due to substantial unpaid debt. Adhera Therapeutics is continuing to work with its advisors to restructure the company and to identify potential strategic transactions, including the Melior transaction to enhance the value of the company. Because of the substantial unpaid debt, if the company does not raise substantial additional capital in the immediate future, it is likely that the company will discontinue all operations and seek bankruptcy protection.공시 • Sep 15Adhera Therapeutics, Inc. Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes DrugsAdhera Therapeutics, Inc. provided shareholders an update on corporate strategy and planned clinical development of MLR-1019 (armesocarb) and MLR-1023 (tolimidone). On July 29, 2021 and August 24, 2021, respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinson’s disease (PD) and MLR-1023 for Type 1 diabetes. Adhera will develop MLR-1019 as a new class of drug for PD and, to the best of the Company’s knowledge, as the only drug candidate designed to address both movement and non-movement symptoms of PD. Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications. Based upon previous work conducted by licensing partner Melior Pharmaceuticals II, LLC (“Melior 2”), a clear understanding of MLR-1019’s mechanism of action, abundant pre-clinical research and decades of clinical data on mesocarb, which is chemically related to armesocarb, Adhera intends to initiate a Phase 2a clinical trial in an Eastern European jurisdiction where mesocarb still has marketing registration. The Company will undertake a parallel process in the U.S. with Investigational New Drug (IND)-enabling studies. Adhera believes that the comprehensive historical data in combination with new data from clinical trials in Europe will facilitate an accelerated development pathway in the U.S. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b clinical trials in patients with Type 2 diabetes. The Company will work under the IND of license partner Melior Pharmaceuticals I, Inc. (“Melior 1”) to continue clinical development of MLR-1023, with a transition to Type 1 diabetes as the target indication. The decision to focus on Type 1 diabetes was supported by multiple factors, including: Compelling work by an independent investigator in Canada demonstrating the ability of MLR-1023 to confer unique benefits to pancreatic beta cell (insulin producing cells) in models of Type 1 diabetes. Longer period of market exclusivity for Type 1 diabetes compared to Type 2 diabetes. Blue sky opportunity for an oral Type 1 diabetes drug (market for oral Type 2 diabetes drugs is already crowded). Cost to market is substantially lower for Type 1 diabetes compared to Type 2 diabetes.공시 • Aug 18Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 08/17/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 25Adhera Therapeutics, Inc. Contemplates Bankruptcy Adhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of May 24, 2021. According to SEC filing, Company said that its has been working with its advisors to restructure the company with all the resources available. Adhera is identifying potential strategic transactions to enhance the value of the company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to legacy RNA interference programs, as well as business combination transactions with operating companies. There can be no assurance that the company will be successful at identifying any such transactions, that it will continue to have sufficient resources to actively attempt to identify such transactions, or that such transactions will be available upon terms acceptable to the company or at all. If Adhera do not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the company will discontinue all operations and seek bankruptcy protection.공시 • May 18Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 05/17/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 03Adhera Therapeutics, Inc. announced delayed annual 10-K filingOn 04/01/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 19Adhera Therapeutics, Inc. Contemplates BankruptcyAdhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of November 18, 2020. According to SEC filing, Company said that it has been working with its advisors to restructure the company and to identify potential strategic transactions to enhance the value of the company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to legacy RNA interference programs, as well as business combination transactions with operating companies. If the Company does not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the Company will discontinue all operations and seek bankruptcy protection.공시 • Nov 18Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 11/16/2020, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 15Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 08/14/2020, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jul 17Adhera Therapeutics, Inc. Appoints Andrew Kucharchuk as the Chief Executive OfficerOn July 7, 2020, the Board of Directors of Adhera Therapeutics, Inc. engaged Mr. Andrew Kucharchuk to serve as the Chief Executive Officer of the Company effective immediately. Mr. Kucharchuk, previously served as President and Chief Financial Officer of OncBioMune Pharmaceuticals, Inc. from February 2016 until June 2020.공시 • Jul 07Adhera Therapeutics, Inc. May File for BankruptcyAdhera Therapeutics, Inc. may file for bankruptcy, as of July 6, 2020. The company may file for bankruptcy if it fails to get the required financing.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ATRX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ATRX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Adhera Therapeutics 배당 수익률 vs 시장ATRX의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ATRX)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (ATRX) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ATRX 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ATRX 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ATRX 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ATRX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 08:11종가2026/03/30 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Adhera Therapeutics, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 19Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive OfficerOn January 12, 2024, Adhera Therapeutics, Inc. received notice from Zahed Subhan that he was resigning as the company’s Chief Executive Officer and as a member of the Board of Directors. Mr. Subhan’s decision to resign as Chief Executive Officer and member of the company’s Board of Directors was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
공시 • Jan 18Adhera Therapeutics, Inc. Announces Board ResignationsOn January 9, 2024, Adhera Therapeutics, Inc. received notice from Trond K. Waerness that he was resigning from Board of Directors effective January 12, 2024. Mr. Waerness’ decision to resign as director was not the result of any disagreement with the company on any matter relating to the Company’s operations, policies, or practices. Further, on January 12, 2024, the company received notice from Zahed Subhan that he was resigning as the company’s Chief Executive Officer and as a member of the Company’s Board of Directors. Mr. Subhan’s decision to resign as Chief Executive Officer and member of the Company’s Board of Directors was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
공시 • Nov 17Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 11/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 17Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 16Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 05/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jan 26Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 DiabetesAdhera Therapeutics, Inc. announced that the company is to commence a dose finding study of MLR-1023 (tolimidone) in Type 1 Diabetes in collaboration with the Alberta Diabetes Institute (ADI) at the University of Alberta (U of A), located in Edmonton, Alberta, Canada. The company and U of A are finalizing the details of the trial, which are expected to be released shortly. The results of the study will also be utilized to optimize the dose range used in Adhera’s forthcoming Phase 2 multi-center clinical trial of MLR-1023 in Type 1 Diabetes. It is anticipated that the ADI will also participate in the multi-center study. MLR-1023, a lyn kinase activator with potent beta cell proliferation activity, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies. Adhera will focus its initial clinical trials on patients with Type 1 Diabetes where the Company can benefit from several factors, including the existing safety profile, which is expected to undergird the drug candidate moving directly into Phase 2 clinical trials and a shorter and less expensive clinical pathway compared to Type 2 Diabetes. Independent research has demonstrated robust therapeutic effects of MLR-1023 in Type 1 Diabetes preclinical models. There is a large addressable market due to the lack of alternative treatment options in Type 1 Diabetes aside from insulin injections or an insulin pump. In Type 1 Diabetes patients, the pancreas produces little to no insulin. At a cellular level, the immune system attacks pancreatic beta cells that produce insulin, leaving the patient with deficient levels of insulin to control blood glucose and a resulting dependency on exogenous insulin. Approximately 20%-30% of Type 1 Diabetes patients have demonstratable amounts of beta cell mass as determined by detectable amount of the insulin synthesis byproduct, C-peptide. Research indicates the potential for MLR-1023 to induce proliferation of a patient’s remaining beta cells. Adhera, alongside independent researchers, hypothesize that if the beta cell mass can be expanded in the C-peptide positive patient population, it may be possible to either reduce or eliminate the exogenous insulin requirement. In addition to the U of A trial, the company is pleased to inform shareholders that progress is being made towards filing an application to uplist to the NASDAQ, a milestone that should yield additional liquidity and allow the Company to secure financing for clinical trials for both MLR-1019 for Parkinson’s Disease and MLR-1023 for Type 1 Diabetes.
공시 • Sep 10+ 1 more updateAdhera Therapeutics, Inc. Announces CEO Changes, Effective September 30, 2022Adhera Therapeutics, Inc. appointed Zahed Subhan as the Company’s Chief Executive Officer, effective September 30, 2022. Mr. Kucharchuk will continue to serve as the Company’s Chief Executive Officer until September 30, 2022. Mr. Subhan, 64, has been serving as the Company’s director since November 5, 2021. He has served as the Chief Executive Officer and director of Aestas Pharma Inc. since 2015. Mr. Subhan has also been a director of Eppin Pharma Inc. (“Eppin”) since 2013, and the Chief Executive Officer of Eppin from 2013 to 2018. Mr. Kucharchuk, 41, has served as the Chairman of Board and Chief Executive Officer since July 7, 2020. He has also served on the Board of Directors of Theralink Technologies, Inc. since 2020 after previously serving in such role from September 2015 to March 2017. Previously, he served as President and Chief Financial Officer of Theralink from February 2016 until June 2020, as Chief Executive Officer of Theralink from November 2019 until June 2020, and as Chief Financial Officer of Theralink from 2009 to September 2015. Mr. Kucharchuk has also served as Acting Chief Financial Officer of Theralink from June 2020 to September 2020.
공시 • Jul 20Adhera Therapeutics, Inc. (OTCPK:ATRX) enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group.Adhera Therapeutics, Inc. (OTCPK:ATRX) enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group on July 19, 2022. While best efforts are anticipated to advance the Heads of Terms agreement to an executed definitive agreement pursuant to which Adhera will acquire PGT, no assurances of such a development are expressed, implied, or guaranteed.
공시 • Jun 29Adhera Therapeutics, Inc., Annual General Meeting, Aug 18, 2022Adhera Therapeutics, Inc., Annual General Meeting, Aug 18, 2022, at 10:00 US Eastern Standard Time. Agenda: To elect four directors for a one-year term expiring at the next annual meeting of stockholders; to ratify the selection of Salberg & Company, P.A. as the Company’s independent registered public accounting firm for the year ending December 31, 2022; to approve amendment(s) to the Company's Certificate of Incorporation to effect one or more reverse stock splits of the Company's issued and outstanding shares of common stock, par value USD 0.006 per share, at a ratio to be determined in the discretion of the Company's Board of Directors within a range of one-for-two through one-for-200, provided that in no event shall such amendments collectively exceed a reverse stock split ratio of one-for-200; and to consider other matters.
공시 • May 20+ 1 more updateAdhera Therapeutics, Inc. Planning to Initiate A Phase 2 Clinical Trial of Mlr-1023 as new Treatment for Type 1 DiabetesAdhera Therapeutics, Inc. announced that it is planning to initiate a Phase 2 clinical trial of MLR-1023 as anew treatment for Type 1 Diabetes where its role in pancreatic beta cell protection and proliferation represents a potential major breakthrough in diabetes care. MLR-1023 is a next generation, non-PPAR insulin sensitizer via lyn kinase activation that has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and 2b diabetes studies. The active pharmaceutical ingredient (API) for this trial has already been manufactured. The Company is also actively working to initiate a Phase 2a study to evaluate MLR-1019 for Parkinson’s Disease. To the best of the Company’s knowledge, MLR-1019 is the only drug in development that has the potential to address both movement and non-movement aspects of the disease. The trial is designed to enroll Parkinson’s Disease patients with L-DOPA induced dyskinesia, a frequent and potential disabling motor side effect of levodopa therapy. The API for this trial has now entered the manufacturing process.
공시 • Apr 03Adhera Therapeutics, Inc. announced delayed annual 10-K filingOn 04/01/2022, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 24Adhera Therapeutics, Inc. Contemplates BankruptcyAdhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of November 22, 2021. According to SEC filing, Company is in financial distress due to substantial unpaid debt. Adhera Therapeutics is continuing to work with its advisors to restructure the company and to identify potential strategic transactions, including the Melior transaction to enhance the value of the company. Because of the substantial unpaid debt, if the company does not raise substantial additional capital in the immediate future, it is likely that the company will discontinue all operations and seek bankruptcy protection.
공시 • Sep 15Adhera Therapeutics, Inc. Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes DrugsAdhera Therapeutics, Inc. provided shareholders an update on corporate strategy and planned clinical development of MLR-1019 (armesocarb) and MLR-1023 (tolimidone). On July 29, 2021 and August 24, 2021, respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinson’s disease (PD) and MLR-1023 for Type 1 diabetes. Adhera will develop MLR-1019 as a new class of drug for PD and, to the best of the Company’s knowledge, as the only drug candidate designed to address both movement and non-movement symptoms of PD. Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications. Based upon previous work conducted by licensing partner Melior Pharmaceuticals II, LLC (“Melior 2”), a clear understanding of MLR-1019’s mechanism of action, abundant pre-clinical research and decades of clinical data on mesocarb, which is chemically related to armesocarb, Adhera intends to initiate a Phase 2a clinical trial in an Eastern European jurisdiction where mesocarb still has marketing registration. The Company will undertake a parallel process in the U.S. with Investigational New Drug (IND)-enabling studies. Adhera believes that the comprehensive historical data in combination with new data from clinical trials in Europe will facilitate an accelerated development pathway in the U.S. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b clinical trials in patients with Type 2 diabetes. The Company will work under the IND of license partner Melior Pharmaceuticals I, Inc. (“Melior 1”) to continue clinical development of MLR-1023, with a transition to Type 1 diabetes as the target indication. The decision to focus on Type 1 diabetes was supported by multiple factors, including: Compelling work by an independent investigator in Canada demonstrating the ability of MLR-1023 to confer unique benefits to pancreatic beta cell (insulin producing cells) in models of Type 1 diabetes. Longer period of market exclusivity for Type 1 diabetes compared to Type 2 diabetes. Blue sky opportunity for an oral Type 1 diabetes drug (market for oral Type 2 diabetes drugs is already crowded). Cost to market is substantially lower for Type 1 diabetes compared to Type 2 diabetes.
공시 • Aug 18Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 08/17/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 25Adhera Therapeutics, Inc. Contemplates Bankruptcy Adhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of May 24, 2021. According to SEC filing, Company said that its has been working with its advisors to restructure the company with all the resources available. Adhera is identifying potential strategic transactions to enhance the value of the company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to legacy RNA interference programs, as well as business combination transactions with operating companies. There can be no assurance that the company will be successful at identifying any such transactions, that it will continue to have sufficient resources to actively attempt to identify such transactions, or that such transactions will be available upon terms acceptable to the company or at all. If Adhera do not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the company will discontinue all operations and seek bankruptcy protection.
공시 • May 18Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 05/17/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 03Adhera Therapeutics, Inc. announced delayed annual 10-K filingOn 04/01/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 19Adhera Therapeutics, Inc. Contemplates BankruptcyAdhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of November 18, 2020. According to SEC filing, Company said that it has been working with its advisors to restructure the company and to identify potential strategic transactions to enhance the value of the company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to legacy RNA interference programs, as well as business combination transactions with operating companies. If the Company does not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the Company will discontinue all operations and seek bankruptcy protection.
공시 • Nov 18Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 11/16/2020, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 15Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 08/14/2020, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jul 17Adhera Therapeutics, Inc. Appoints Andrew Kucharchuk as the Chief Executive OfficerOn July 7, 2020, the Board of Directors of Adhera Therapeutics, Inc. engaged Mr. Andrew Kucharchuk to serve as the Chief Executive Officer of the Company effective immediately. Mr. Kucharchuk, previously served as President and Chief Financial Officer of OncBioMune Pharmaceuticals, Inc. from February 2016 until June 2020.
공시 • Jul 07Adhera Therapeutics, Inc. May File for BankruptcyAdhera Therapeutics, Inc. may file for bankruptcy, as of July 6, 2020. The company may file for bankruptcy if it fails to get the required financing.